Huizermaatweg 460, 1276 LM, Huizen, the Netherlands
24Care develops Patient Self-management services, at this stage in particular for diabetes and chronic heart failure. Our diagnostic tools will offer home measurement by eHealth and self-management for blood pressure, weight, cholesterol, HbAc1, triglycerides, blood glucose, daily activity and others. Our system will serve patients to manage their disease independently to referring physicians. The system is in pilot, validation in process in cooperation with 2 Universities. All data are automatically stored in the patients' own file, the Personal Patient Dossier. Referring physicians will set personalized boarders and have access to these data. Automatic messaging to patients and physicians ensures early intervention. Improved quality of life, reduction of hospitalization, lower morbidity and cost savings are main objectives. Self-management will be supported by video consulting and, for pharmacists, medication adherence control. Partners for local distribution or licensing are welcome.
Recent news: First video consult between cardiologist Uiversity Medical Centre Utrecht and Chronic Heart Failure patient in Empower project / DiabetesStation impressive innovation during Dutch Embassadors Meeting at Erasmus Medical Centre - Rotterdam
Cluster: Amsterdam Economic Board
2, Alfred Kasler - 44000 - NANTES, France
Axelife SAS has developed a non intrusive diagnostic medical device : "pOpmètre" that measures the arterial stiffness which is the most predictive biomarkuer of Stroke, cognitive impairment, myocardial infarction, kidney failure, diabetes, hypertension, cholesterol... This technique represents a good alternative for the measurement of the arterial aging in outpatient and epidemiological settings. This is a diagnostic device of the arteriosclerosis for medical centers, hospital, and outpatient clinic use. As is in the guidelines for the Cardiovascular risk diagnosis and evaluation of scientific associations. We are looking for distributors.
Cluster: Atlanpole Biotherapies
100 Route des Houillères, 13590 Meyreuil, France
Axyn is a brand new robotics start-up founded in September 2014. We are currently developing a robot that is able to move autonomously in order to assist people with reduced mobility and support their caregivers. We focus on the healthcare industry and on Silver Valley, which fosters the conditions to the development of the senior market on a national and international level.
In the first instance, the robot is designed for retirement homes, medical centres and institutes. Axyn aims at designing and building service robots that really add tangible value. That is why we work closely with APPROCHE, an association that gathers doctors and ergotherapists. Together with them, we identify the needs of elderely people and patients and validate technological solutions. Only the combined work of robotics experts and financial and marketing specialists made it possible to develop this robot that is based on an entire patent portfolio, being established at the moment.
Next to their assistant robot, Axyn Robotics has developed Ubyx, a telepresence robot. This robot is based on an open-source platform to improve and to foster usages. We want Ubyx to be accessible for everyone, so that the kit will cost less than 1000 Euro.
9 Route de Chavagne BP 36 – FR 35310 MORDELLES – France
BA Healthcare designs, produces and deploys mobile wheel-based autonomous platforms for various applications.
BA Healthcare developed with GE Healthcare a special AGV (Automated Guided Vehicle) that is embedded in a full solution for interventional radiography. The system is commercialized by GE Healthcare as the Discovery IGS.
BA Healthcare is also leading other projects in the fields of rehabilitation robotics and people autonomy.
- A walk rehabilitation robot which is a therapeutic device that will help patients who has suffered from stroke or other neurological patients to learn to rewalk. Hospital and rehabilitation center will use these devices on a daily basis to help patients to walk earlier.
- A new device that will help elderly and/or disable people to stay home longer by giving them more autonomy to move.
BA HEALTHCARE is also willing to provide its expertise in precise motion control and reliable autonomous robotics to any healthcare project.
Watch our company video (French - click on the menu bar to display subtitles in English):
ICM-iPeps, 47 bld de l'hopital, 75013 Paris, France
BioSerenity develops non invasive point of care medical devices for the diagnosis and monitoring of pathologies that require long term recordings.
- Wearable Point of Care systems for the diagnosis of Epilepsy (TRL7)
- Wearable PoC systems for the diagnosis of sleep disorders (TRL6)
- Wearable cardiac halters (TRL5)
- Medical Big Data platform (TRL6)
The company holds 8 patents and is happy to partner.
Institute of LifeScience 2, University of Swansea, Swansea, Wales, SA2 8PP UK
Developing next generation of low blood trauma Ventricular Assist Devices for Advanced Heart Failure. Currently at Design Freeze and in animal verification studies. Target market - the 400 cardiac surgery centres implanting VADs in end stage Advanced Heart Failure patients in Europe/US and advanced medical markets. Currently seeking funding for First-In-Human studies.
12 rue Albert Roussel, 75017 Paris, France
Cardiawave, located in Paris, France, began operations in October 2014. Cardiawave is a spin-off from the French-based Langevin Institute (CNRS/INSERM), the world leader in ultrasound imaging and therapy.
We develop a unique non-invasive, real-time image-guided medical device for heart valve disease treatment (mainly calcified aortic stenosis) using a cutting-edge histotripsy technology with no thermal injury.
We are looking for R&D partners and would consider entering any research consortium in the field of ultrasound-guided extracorporeal shock wave therapy.
1 - 2 Heol Rhosyn, Dafen, Llanelli, Carmarthenshire, SA14 8QG UK
Chromogenex Technologies Ltd is the UK’s leading developer and manufacturer of advanced light and laser technology systems for use in medical and cosmetic procedures. Since its beginnings in 1986, Chromogenex has applied ground-breaking innovations in the laser industry to respond to the dermatological and cosmetic challenges facing medical professionals.
Today practitioners worldwide use Chromogenex products to offer safe, effective treatments for a wide range of conditions using non-invasive procedures. These currently include the treatment of vascular and pigmented lesions, psoriasis, vitiligo and acne and well as permanent hair removal, skin rejuvenation and fat reduction. Chromogenex continues to focus on the high growth export markets of Brazil, the Far East, India and South Africa as well as Europe and North America.
This continued rapid growth, despite the current challenging economic climate, follows substantial sales in the USA of our top selling slimming product, iLipo. This safe, non-surgical slimming device was introduced into the North American market just last July and already accounts for over 60% of the company’s total sales.
Significant investment in R&D each year enables Chromogenex to remain a market leader. We continue to look to the future. Our new products include the very latest in body contouring and fat reduction, the i-Lipoxcell. www.chromogenex.com/ilipoxcell
9 rue des Croix Roses, 22400 Saint-Alban, France
Clarisse Lecourt founded Claripharm™ after the birth of her daughter with the desire to develop a range of products designed for women’s post-partum comfort and for pain relief following gynaecologic, urologic, proctologic or intimate cosmetic surgery. Together with a group of surgeons, she created a flexible shell for intimate protection designed for women’s bodies: Claricare™. It is a significant advancement in the treatment of pain following any intimate surgery. Claricare™ is a medical device designed and patented by Claripharm™. It is a standard size suitable for all female body shapes and provides a stable and painless sitting position (avoids rubbing) at hospital and at home during the entire healing process. The device has been tested clinically and is now commercialized. It is currently marketed directly through a Claripharm™ salesforce in France and through distributors internationally. In Europe, Belgium, Luxembourg and Switzerland have started selling the device.
International Development is continuing with market studies being conducted in Germany, Austria and Spain among others. An important step has recently been achieved when Claripharm™ obtained an FDA approval for Claricare™to be commercialized in the USA through a local distributor. Alongside its flagship product, Claripharm™ has developed several other intimate care products. Claripharm is also developing two new projects (TRL stage 2 and 3) aiming at pain relief.
In 2014 Claripharm was awarded an innovation prize from a local entrepreneurial group of companies and in April 2015 Claripharm obtained a prize from a local investor group for its rapid growth as a startup company
4A, rue Jean Sonet, 5032 Gembloux. Belgium
Coris BioConcept is a middle-sized company, ISO certified (ISO 9001, ISO 13485) and specialized in developing, manufacturing and marketing rapid diagnostics. These lateral flow testst (ICT) are based on colloidal gold nanoparticles or latex microspheres. This ICT tests allow for detection of infectious diseases including enteric pathogens and respiratory pathogens. A new range of products have been recently developed for detecting Carbapenemase-Producing Enterobacteriaceae (CPE). Five parameters are targeted, i.e. OXA-48, KPC, NDM, VIM and IMP. These lateral flow assays detect specifically CPE from bacterial colonies in less than 15 minutes. OXA48 and KPC are already clinically validated. Coris has also developed a multiplex molecular platform based on the microfluidic technology for multiplex diagnosis. This platform is made of an instrument and dedicated microfluidic chips. Two products for identifying Gram positive and Gram negative bacteria from blood-culture along with some resistance parameters are developed. A third product for multiple respiratory pathogens detection will be clinically validated in the next few months.